IGC Pharma Expands Alzheimer’s Trial With Mount Sinai Clinical Site

IGC Pharma announced the addition of the Icahn School of Medicine at Mount Sinai in New York as a new clinical site for its ongoing Phase 2 CALMA trial, evaluating IGC-AD1 for agitation associated with Alzheimer’s disease. The company says the study is advancing toward completion, with approximately 80% of targeted participants having completed trial participation. IGC believes adding world-class clinical institutions supports stronger patient access, data integrity, and final-stage execution as the CALMA program moves toward database lock and top-line analysis. The trial represents part of the company’s broader effort to develop therapies targeting neurological conditions linked to Alzheimer’s disease. #IGCPharma #AlzheimersDisease #Biotech #ClinicalTrials #HealthcareInnovation #Neurology #DrugDevelopment #MedicalResearch #Alzheimers #MountSinai #Pharmaceuticals #BrainHealth #Healthcare #JaneKing #NewsOut